Despite the robust anti-tumor effects demonstrated in certain patients by α-PD-1/PD-L1 therapy, the majority are unable to derive sole benefits from this treatment, owing to the existence of various primary and secondary immune escape mechanisms (4). This evidence concerns the gene CD274 and neoplasm.